2024
O 09 Radiotherapy utilization and outcomes from a contemporary study of brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin lymphoma
Hoppe B, Castellino S, Pei Q, Charpentier A, Mailhot-Vega R, Roberts K, Parikh R, Flampouri S, Kelly K, Hodgson D. O 09 Radiotherapy utilization and outcomes from a contemporary study of brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin lymphoma. International Journal Of Particle Therapy 2024, 11: 100032. DOI: 10.1016/j.ijpt.2024.100032.Peer-Reviewed Original Research
2023
Radiotherapy Utilization and Outcomes on a Contemporary Trial for Pediatric High-Risk Hodgkin Lymphoma Study
Hoppe B, Castellino S, Pei Q, Charpentier A, Keller F, Vega R, Roberts K, Parikh R, Punnett A, Parsons S, McCarten K, Flampouri S, Kessel S, Wu Y, Cho S, Kelly K, Hodgson D. Radiotherapy Utilization and Outcomes on a Contemporary Trial for Pediatric High-Risk Hodgkin Lymphoma Study. International Journal Of Radiation Oncology • Biology • Physics 2023, 117: s62-s63. DOI: 10.1016/j.ijrobp.2023.06.362.Peer-Reviewed Original ResearchProgression-free survivalBrentuximab vedotinABVE-PCIrradiated patientsMediastinal adenopathyRadiotherapy utilizationContemporary trialsRT modalityOpen-label phase 3 studyExcellent progression-free survivalUse of PTProgression-free survival ratesProton therapyHodgkin's lymphoma studyUtilization of RTSevere acute toxicityPhase 3 studyPediatric Hodgkin lymphomaSimilar acute toxicityAcute toxicityMATERIAL/METHODSDifferent RT modalitiesEligible patientsMedian followPediatric patients